Cognitive decline prevention may start in the gut, study suggests
By
Kristen Fischer
Jul 25, 2023
Probiotics could aid in preventing cognitive decline that happens during aging, according to a study released at the American Society for Nutrition conference this week in Boston. The research could make...
Clinical briefs for Monday, June 26
By
Alicia Lasek
Jun 26, 2023
GAO chides CMS over delayed nursing home reporting, antipsychotic transparency … Over 1.3 billion globally will have diabetes by 2050, study finds … Moderna requests FDA authorization for updated COVID...
Program that diagnosed fractures virtually led to fewer ER visits for LTC residents: study
By
Alicia Lasek
May 14, 2023
A program that enabled virtual diagnosis and on-site fracture care kept 100% of participating LTC residents out of the emergency department and cut the need for clinic visits, a new study reveals.
Long-term care’s zeal for foreign nurses a ‘Band-Aid’ solution: researchers
By
Kimberly Marselas
May 05, 2023
In a new commentary, researchers likened long-term care organizations’ quest to entice immigrant nurses to using a Band-Aid to stop a hemorrhaging workforce wound.
Alzheimer’s drug donanemab finds late-stage trial success, safety concerns
By
Alicia Lasek
May 04, 2023
The experimental drug donanemab appears to halt the progression of Alzheimer’s disease and slow certain measures of clinical decline, new trial data show.
Eli Lilly expects Medicare about-face on Alzheimer’s drugs coverage
By
Alicia Lasek
Apr 23, 2023
New data on Lilly’s experimental drug donanemab may influence CMS’s restrictive stance on coverage of this and other amyloid-busting Alzheimer’s treatments, a company executive says.
Survey: U.S. neurologists would prescribe Leqembi if fully approved
By
Alicia Lasek
Apr 12, 2023
A “healthy proportion” of surveyed neurologists have already begun prescribing the treatment, and nearly all said they planned to do so if traditional FDA approval is granted.
Benefits of Alzheimer’s drug Leqembi persist when treatment is halted, trial shows
By
Alicia Lasek
Apr 09, 2023
A relative slowing of cognitive decline continues for up to two years in patients who stop taking the recently authorized drug, clinical trial data reveal.
CMS: Lapses in infection control, vaccine compliance to garner ‘aggressive’ enforcement
By
Kimberly Marselas
Apr 04, 2023
Federal regulators have quietly put in place new, stricter enforcement measures for nursing homes that struggle to meet infection control and vaccine immunization requirements for residents and staff.
Providers call for broader antipsychotic exclusions to help reduce schizophrenia diagnoses
By
Kimberly Marselas
Mar 31, 2023
Providers and quality experts are questioning why the agency hasn’t done more to review its quality measure for antipsychotic drug use.